142 related articles for article (PubMed ID: 17594597)
21. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
22. Increased β‑catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach.
Liu C; Wu Y; Yu S; Bai J; Li C; Wu D; Zhang Y
Mol Med Rep; 2017 Apr; 15(4):1793-1799. PubMed ID: 28260015
[TBL] [Abstract][Full Text] [Related]
23. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth.
Šteňo A; Bocko J; Rychlý B; Chorváth M; Celec P; Fabian M; Belan V; Šteňo J
Acta Neurochir (Wien); 2014 Mar; 156(3):451-61; discussion 461. PubMed ID: 24452592
[TBL] [Abstract][Full Text] [Related]
24. The clinical significance of MIB-1 labeling index in pituitary adenomas.
Chacko G; Chacko AG; Kovacs K; Scheithauer BW; Mani S; Muliyil JP; Seshadri MS
Pituitary; 2010 Dec; 13(4):337-44. PubMed ID: 20640601
[TBL] [Abstract][Full Text] [Related]
25. Differential gene expression of sirtuins between somatotropinomas and nonfunctioning pituitary adenomas.
Grande IPP; Amorim PVGH; Freire ACTB; Jallad RS; Musolino NR; Cescato VA; da Silva GO; Bronstein MD; Trarbach EB
Pituitary; 2018 Aug; 21(4):355-361. PubMed ID: 29564694
[TBL] [Abstract][Full Text] [Related]
26. The clinical and pathological significance of nitric oxide synthase in human pituitary adenomas: a comparison with MIB-1.
Onishi K; Kamida T; Momii Y; Abe T; Fujiki M
Endocrine; 2014 May; 46(1):154-9. PubMed ID: 24008756
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker.
Pizarro CB; Oliveira MC; Pereira-Lima JF; Leães CG; Kramer CK; Schuch T; Barbosa-Coutinho LM; Ferreira NP
Neuropathology; 2009 Feb; 29(1):40-4. PubMed ID: 18673444
[TBL] [Abstract][Full Text] [Related]
28. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas.
Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G
Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325
[TBL] [Abstract][Full Text] [Related]
29. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness.
Qian ZR; Sano T; Asa SL; Yamada S; Horiguchi H; Tashiro T; Li CC; Hirokawa M; Kovacs K; Ezzat S
J Clin Endocrinol Metab; 2004 Apr; 89(4):1904-11. PubMed ID: 15070963
[TBL] [Abstract][Full Text] [Related]
31. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas.
Hentschel SJ; McCutcheon lE; Moore W; Durity FA
Can J Neurol Sci; 2003 Aug; 30(3):215-9. PubMed ID: 12945944
[TBL] [Abstract][Full Text] [Related]
32. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
33. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland.
Turner HE; Nagy Z; Sullivan N; Esiri MM; Wass JA
Clin Endocrinol (Oxf); 2000 Sep; 53(3):337-44. PubMed ID: 10971451
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of prothymosin alpha is related to pituitary adenoma recurrence but not to adenoma invasiveness and proliferation.
Pawlikowski M; Radek M; Kunert-Radek J; Jaranowska M; Świętosławski J; Winczyk K
Endokrynol Pol; 2014; 65(5):382-6. PubMed ID: 25301489
[TBL] [Abstract][Full Text] [Related]
35. Atypical pituitary adenomas: incidence, clinical characteristics, and implications.
Zada G; Woodmansee WW; Ramkissoon S; Amadio J; Nose V; Laws ER
J Neurosurg; 2011 Feb; 114(2):336-44. PubMed ID: 20868211
[TBL] [Abstract][Full Text] [Related]
36. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
37. Beta human chorionic gonadotropin (beta-hCG) expression in pituitary adenomas: relationship to endocrine function and tumour recurrence.
Doyle PM; Thiryayi WA; Joshi A; du Plessis D; Kearney T; Gnanalingham KK
Pituitary; 2009; 12(3):190-5. PubMed ID: 19005764
[TBL] [Abstract][Full Text] [Related]
38. [Morphofunctional features of non-functioning pituitary adenomas].
Eremkina AK; Dzeranova LK; Pigarova EK; Mokrysheva NG; Dedov II
Arkh Patol; 2019; 81(1):71-78. PubMed ID: 30830109
[TBL] [Abstract][Full Text] [Related]
39. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
40. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].
Miyagami M; Nakamura S
No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
